Finerenone Shows Promise in Slowing Kidney Disease Progression in Non-Diabetic Patients

A major international clinical trial, published in The New England Journal of Medicine, has found that finerenone can significantly slow the decline of kidney function and reduce the risk of serious kidney and cardiovascular complications in individuals with chronic kidney disease (CKD) who do not have diabetes. This research suggests finerenone could become a crucial new treatment option for a large patient population that has historically had limited therapeutic choices beyond standard care.